More than 90% of Americans with mild cognitive impairment go undiagnosed. Cogstate is working to change this.
Cognigram—a HIPAA-compliant, FDA Class II-exempt digital cognitive assessment—is one of their crowning achievements. It's effectively detected mild cognitive impairment in more than 2000 clinical trials.
Yet our early research revealed that commercial adoption of Cognigram would require behavior change across the care continuum. It would require Primary Care Physicians (PCPs) and older Americans to know that a product like Cognigram exists, be motivated to try it, have the skills to use it, and feel supported along the way.
Our research also revealed that the Cognigram report wasn't just a touchpoint; it was a turning point in the assessment experience that could help catalyze the behavior changes needed to increase product adoption and inspire actions that advance brain health in clinics and homes across the U.S. But the visual communication of the results would require significant development.
Public Works was honored to lead the visual redesign of the Cognigram report.
